UNLABELLED: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor AML leaves room for substantial improvement. We discuss treatments that have improved outcome in this group of patients with AML and ongoing/future strategies that might contribute toward incremental gains. BACKGROUND: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. MATERIALS AND METHODS: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. RESULTS: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer. CONCLUSIONS: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.
UNLABELLED: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factorAML leaves room for substantial improvement. We discuss treatments that have improved outcome in this group of patients with AML and ongoing/future strategies that might contribute toward incremental gains. BACKGROUND: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. MATERIALS AND METHODS: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. RESULTS: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer. CONCLUSIONS: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.
Authors: Frederick R Appelbaum; Kenneth J Kopecky; Martin S Tallman; Marilyn L Slovak; Holly M Gundacker; Haesook T Kim; Gordon W Dewald; Hagop M Kantarjian; Sherry R Pierce; Elihu H Estey Journal: Br J Haematol Date: 2006-08-25 Impact factor: 6.998
Authors: Peter Paschka; Guido Marcucci; Amy S Ruppert; Krzysztof Mrózek; Hankui Chen; Rick A Kittles; Tamara Vukosavljevic; Danilo Perrotti; James W Vardiman; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Lars Bullinger; Frank G Rücker; Stephan Kurz; Juan Du; Claudia Scholl; Sandrine Sander; Andrea Corbacioglu; Claudio Lottaz; Jürgen Krauter; Stefan Fröhling; Arnold Ganser; Richard F Schlenk; Konstanze Döhner; Jonathan R Pollack; Hartmut Döhner Journal: Blood Date: 2007-05-07 Impact factor: 22.113
Authors: Richard F Schlenk; Marcelo C Pasquini; Waleska S Pérez; Mei-Jie Zhang; Jürgen Krauter; Joseph H Antin; Asad Bashey; Brian J Bolwell; Thomas Büchner; Jean-Yves Cahn; Mitchell S Cairo; Edward A Copelan; Corey S Cutler; Hartmut Döhner; Robert Peter Gale; Osman Ilhan; Hillard M Lazarus; Jane L Liesveld; Mark R Litzow; David I Marks; Richard T Maziarz; Philip L McCarthy; Stephen D Nimer; Jorge Sierra; Martin S Tallman; Daniel J Weisdorf; Mary M Horowitz; Arnold Ganser Journal: Biol Blood Marrow Transplant Date: 2007-12-20 Impact factor: 5.742
Authors: Steven A Gustafson; Pei Lin; Su S Chen; Lei Chen; Lynne V Abruzzo; Rajyalakshmi Luthra; L Jeffrey Medeiros; Sa A Wang Journal: Am J Clin Pathol Date: 2009-05 Impact factor: 2.493
Authors: Andrew M Brunner; Traci M Blonquist; Hossein Sadrzadeh; Ashley M Perry; Eyal C Attar; Philip C Amrein; Karen K Ballen; Yi-Bin Chen; Donna S Neuberg; Amir T Fathi Journal: Leuk Res Date: 2014-04-12 Impact factor: 3.156